The effect of VP 16-213 on NBT reduction in the normal polymorphonuclear neutrophil.
VP 16-213, an antineoplastic, semisynthetic podophyllotoxin derivative, inhibits NBT reduction in the polymorphonuclear neutrophil (PMN). In the resting PMN an almost complete inhibition is seen at a concentration of 170 microM and a partial inhibition is seen at 17 microM. In PMN's stimulated with zymosan activated serum, partial inhibition is seen at concentrations of both 170 microM and 17 microM. VP 16-213 shows no significant inhibition of NBT reduction in PMN's stimulated by methylene blue. VP 16-213 may alter normal respiratory function in the PMN as reflected by inhibition of NBT reduction.
D000328:Adult; D005047:Etoposide / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D009580:Nitroblue Tetrazolium / Q000378:metabolism*; D010084:Oxidation-Reduction; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013778:Tetrazolium Salts / Q000378:metabolism*
D013778:Tetrazolium Salts; D009580:Nitroblue Tetrazolium; D005047:Etoposide; D011034:Podophyllotoxin